Search bioRxiv⌕ Search

Biology subjects

Yoo, B. C.

Publications and source records attributed to Yoo, B. C..

2 recordsLinked to original sources

GCN5-TADA2B in the SAGA complex provide constitutive fine-tuning control of XRCC1 recruitment and focal retention at DNA damage sites.

The scaffolding protein XRCC1 orchestrates base excision repair (BER) and DNA single strand break repair (SSBR) through extensive protein-protein interactions, and its disruption contributes to human neurological diseases such as SCAR26. Recruitment to DNA damage sites has been traditionally understood to depend exclusively on interaction with PARP1 and PARP1 mediated PARylation. Here, we report for the first time the discovery of GCN5 and TADA2B, components of histone acetyltransferase module of SAGA complex, as novel XRCC1 binding partners that provide critical fine-tuning control over repair site localization. We demonstrate that these SAGA complex components bind XRCC1 constitutively via distinct BRCT domain interactions -- GCN5 mainly to BRCT I and TADA2B mainly to BRCT II -- independent of DNA damage status or GCN5s acetyltransferase activity. Depletion of either protein significantly impairs XRCC1 recruitment efficiency, while paradoxically rescuing focal retention defects in BRCT II deficient XRCC1 mutants. This dual regulatory behavior reveals a regulatory mechanism where constitutive protein interactions optimize normal XRCC1 function but become counterproductive when XRCC1 is structurally compromised, particularly in the BRCT II domain. Analysis of the SCAR26 associated variant, which disrupts TADA2B binding while maintaining LIG3 interaction, confirms this dual regulatory model and provides molecular insights into potential disease pathophysiology. Our findings establish a ready-for-action model of DNA repair coordination where protein complexes pre-organize repair machinery for immediate deployment upon damage detection, expanding our understanding of BER regulation.

cell biology↗

Metastatic function of METTL18 in breast cancer via actin methylation and Src

Recently, a SET domain containing 3 (SETD3) was identified as an actin histidine methyltransferase, functioning to control replication and pathogenesis in multiple mouse models for enterovirus infection as well as the regulation of smooth muscle contractility linked to primary dystocia. Here, in this study, we report another type of actin histidine methyltransferase, METTL18, that regulates the metastatic potential of breast cancer in human. Among methyltransferases, METTL18 was highly amplified in human breast cancer. In particular, poor prognosis was associated with high expression of METTL18 in HER2-negative breast cancer patients. This gene product was also found to be a critical component of metastatic responses. Loss of METTL18 expression significantly reduced metastatic responses of breast tumor cells both in vitro and in vivo. Mechanistically, it was observed that METTL18 increased actin polymerization, upregulated complex formation with HSP90AA1 and Src, enhanced the activity of an intermediate form of Src with tyrosine phosphorylation at both Y416 and Y527, and induced cellular metastatic responses, including morphological change, migration, and invasion of MDA-MB-231 cells in vitro and in mice. Methylated actin at His73 served as a critical site for interaction with HSP90AA1 and Src to activate p85/PI3K and STAT3. Our findings suggest that METTL18 plays critical roles in metastatic responses of HER2-negative breast cancer cells via actin polymerization and the generation of an intermediate form of Src.

cancer biology↗